Microaxial flow-pump support in patients with cardiogenic shock: a review of the literature

Purpose of review The purpose of this review is to summarize the current evidence in the treatment of patients with cardiogenic shock focusing on the use of microaxial flow pump (mAFP) support. Recent findings In recent years, the use of mAFP for the treatment of patients with cardiogenic shock has increased. This review summarizes the most important studies on this topic from recent years with a focus on patients with ST-elevation myocardial infarction-related cardiogenic shock (STEMI-CS). Summary Based on the results of a recently published randomized trial (DanGer Shock study), it is essential for clinical practice to carry out a differentiated patient selection to achieve a survival benefit. Specifically, according to the current findings, patients with STEMI-CS, intact right ventricular function, and a low probability of hypoxic brain damage appear to benefit most from treatment with mAFP. A subgroup analysis also suggests a benefit to patients younger than 77 years old.